Chinese pharmaceuticals manufacturer Sichuan Languang Development has issued offshore US bonds maturing within five years, subject to the company’s capital needs and other factors, to raise up to $1bn in gross proceeds.
The company plans to use the proceeds towards repayment of debts and working capital.
Go deeper with GlobalData
Avadel Pharmaceuticals (Avadel) plans to raise $125m through the private placement of exchangeable senior notes due 2023.
The placement was made through its subsidiary Avadel Finance Cayman and subscribed to by qualified institutional buyers.
The initial buyers will be granted a 30-day option to purchase another $18.75m in a principal amount of notes.
Based in Ireland, Avadel Pharmaceuticals is a specialist pharmaceutical company, which plans to use the proceeds for working capital and for general corporate purposes.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataCerecor has signed an agreement with Avadel Pharmaceuticals and its subsidiaries, including Avadel Pharmaceuticals (USA), Avadel Pediatrics, FSC Therapeutics, and Avadel US Holdings to purchase the rights to four of the latter’s marketed paediatric products.
The four products include Karbinal ER, AcipHex Sprinkle, Cefaclor for Oral Suspension, and Flexichamber.
The deal is expected to strengthen the US-based biopharmaceutical company’s paediatric product portfolio.
Cerecor has simultaneously signed a licensing agreement with Flamel Ireland for the use of its LiquiTime and Micropump technology for the development of four product formulations.
US-based pharmaceutical company Dare Bioscience has issued shares of its common stock and warrants in a public offering.
The proceeds are intended to be used for working capital and general corporate purposes.
ROTH Capital Partners has been appointed as the underwriter for the transaction.
Chinese pharmaceutical company Shanghai Fosun Pharmaceutical (Group) plans to raise CNY5bn ($791.33m) through a public offering of corporate bonds.
GNC Holdings Inc (GNC) has issued convertible perpetual preferred shares in a private placement to raise $300m.
Harbin Pharmaceutical Group Holding (Harbin Pharma) has subscribed to the placement and will own 40% interest in GNC, upon the completion of the transaction.
Based in the US, GNC Holdings is a producer of health, wellness and performance products.
The company plans to use the proceeds for the repayment of outstanding debt and for general corporate needs.
GNC has simultaneously formed a strategic partnership with Harbin Pharma for the production, marketing and distribution of GNC-branded products in China.
